Analyzing Viking Therapeutics' Fundamentals Before Investing

By Susan Ramirez • Tuesday, April 09 15:13 • Permanent Link

One of the losers of today's trading session was Viking Therapeutics. Shares of the Pharmaceutical company plunged -4.7%, and some investors may be wondering if its price of $72.28 would make a good entry point. Here's what you should know if you are considering this investment:

Viking Therapeutics has moved 328.9% over the last year, and the S&P 500 logged a change of 26.6%
VKTX has an average analyst rating of buy and is -36.49% away from its mean target price of $113.8 per share
Its trailing earnings per share (EPS) is $-0.91
Viking Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of -79.4 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-1.52 and its forward P/E ratio is -47.6
The company has a Price to Book (P/B) ratio of 20.77 in contrast to the S&P 500's average ratio of 2.95
Viking Therapeutics is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
The company has a free cash flow of $-42364876, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.